Nervous System News and Research

Latest Nervous System News and Research

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

MLL team finds 454 Sequencing technology promising for leukemia genetic characterization

This week at the 51st American Society for Hematology Annual Meeting, a team of researchers from the MLL Munich Leukemia Laboratory presented results from a series of groundbreaking studies which explore alternative, high-throughput 454 Sequencing methods for distinguishing and characterizing the many forms of leukemia and myeloproliferative disorders.

9 Dec 2009

Ontario chiropractors offer tips to help ward off common seasonal injuries

With the season's first winter storm looming, Ontarians can expect to get quite a workout clearing the driveway - especially when you consider that a single shovelful of snow weighs 5 to 7 pounds. Improper shoveling can lead to minor strains and sore muscles, and can also cause more serious injuries.

9 Dec 2009

State and national medical societies join to oppose the 'Patient Protection and Affordable Care Act'

Tens of thousands of physicians in America, who are deeply concerned over the direction of health reform legislation, have joined forces to deliver a strong message to Congress: it’s not too late to get it right; slow down and change course.

9 Dec 2009

Successful reduction in the levels of aggregated Abeta with GSMs

EnVivo Pharmaceuticals today reported the successful reduction in the levels of aggregated Abeta or Beta-Amyloid in an aged transgenic model (Tg2576) of Alzheimer's disease with its lead gamma-secretase modulator (GSM) EVP-0962. The aggregated Abeta, containing predominately oligomeric and larger Abeta fibrillar species, is considered to be the toxic entity in Alzheimer's disease.

9 Dec 2009

FDA cleared, non-invasive prescription therapeutic device for NVP now available

PrimaBella™, the only non-invasive prescription therapeutic device cleared by the U.S. Food and Drug Administration (FDA) for the treatment of nausea and vomiting due to pregnancy (NVP), is now available. Providing a non-invasive, drug-free treatment for morning sickness, PrimaBella™ has been proven to be safe for both mother and developing baby and can offer quick relief -- the majority of patients report an immediate improvement in NVP symptoms.

9 Dec 2009

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

Results of two new studies support the use of the intravenous formulation of the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy in clinical settings where oral AED therapy is temporarily not feasible.

8 Dec 2009

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CeNeRx BioPharma, Inc., a clinical stage company developing innovative treatments for diseases of the central nervous system, today announced that a newly published PET imaging study in human subjects confirms that CeNeRx's novel compound TriRima(TM) reversibly inhibits MAO-A (monoamine oxidase A), an enzyme in the brain that plays a key role in the regulation of mood.

8 Dec 2009

CAM314 randomized Phase 3 clinical trial results released

Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath (alemtuzumab) in combination with Fludara (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to single-agent Fludara.

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Multi-institutional team explores regenerative techniques for injured spinal cords

For more than 400 years, scientists have studied the amazing regenerative power of salamanders, trying to understand how these creatures routinely repair injuries that would usually leave humans and other mammals paralyzed - or worse.

8 Dec 2009

Study shows positive association between adolescent fitness and cognitive performance

In the first study to demonstrate a clear positive association between adolescent fitness and adult cognitive performance, Nancy Pedersen of the University of Southern California and colleagues in Sweden find that better cardiovascular health among teenage boys correlates to higher scores on a range of intelligence tests - and more education and income later in life.

8 Dec 2009

$225,000 funding for promising epilepsy research

The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

7 Dec 2009

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

7 Dec 2009

UCB presents data on Vimpat AED at AES meeting

UCB today announced new findings on its antiepileptic drug (AED) Vimpat® that offer additional clinical evidence supporting the use of this AED as adjunctive therapy in adult patients with partial-onset seizures. Results of presented research demonstrate sustained efficacy in adult patients taking Vimpat® for up to three years, and a consistent long-term tolerability profile.

7 Dec 2009

Study explains how circadian rhythms can drive feeding and metabolism behaviors

One of the pioneers in research on sleep:wake circadian genes, Amita Sehgal, Ph.D., has discovered that fruit flies' appetite and consumption are controlled by two rival sets of clocks, one in neurons and the other in the fly fat body, which is analogous to the liver.

6 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the National Cancer Institute.

5 Dec 2009

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur more often in people who said they had been diagnosed with epilepsy versus those without an epilepsy diagnosis, according to a survey of approximately 173,000 households across the U.S.

4 Dec 2009

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

StemCells, Inc. announced today that it welcomes the approval yesterday by the National Institutes of Health (NIH) of the first 13 human embryonic stem cell (hESC) lines for use in NIH-funded research under the NIH Guidelines for Human Stem Cell Research adopted in July 2009.

4 Dec 2009

Nervous System News and Research

Latest Nervous System News and Research

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

MLL team finds 454 Sequencing technology promising for leukemia genetic characterization

Ontario chiropractors offer tips to help ward off common seasonal injuries

State and national medical societies join to oppose the 'Patient Protection and Affordable Care Act'

Successful reduction in the levels of aggregated Abeta with GSMs

FDA cleared, non-invasive prescription therapeutic device for NVP now available

Results of two new studies support the use of intravenous Vimpat for patients in clinical settings

CeNeRx BioPharma's TriRima reversibly inhibits MAO-A, confirms PET imaging study

CAM314 randomized Phase 3 clinical trial results released

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Multi-institutional team explores regenerative techniques for injured spinal cords

Study shows positive association between adolescent fitness and cognitive performance

$225,000 funding for promising epilepsy research

FDA provides a Complete Response Letter for Somaxon Pharmaceuticals' Silenor NDA

UCB presents data on Vimpat AED at AES meeting

Study explains how circadian rhythms can drive feeding and metabolism behaviors

Stem cell treatment: A new hope for Multiple Sclerosis

Late recurrence of Ewing sarcomas and astrocytomas: A risk for some pediatric cancers

Analysis explores the importance of CNS-related conditions and their impact on epilepsy management

StemCells welcomes NIH's approval of the first 13 human embryonic stem cell lines for research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Nervous System News and Research

Latest Nervous System News and Research

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Newsletters you may be interested in